Literature DB >> 10454217

Pharmacology of antisense oligonucleotide inhibitors of protein expression.

S R Cooper1, J K Taylor, L J Miraglia, N M Dean.   

Abstract

The dramatic increase in recent years of both the amount and rate of accumulation of novel genomic sequence information has generated enormous opportunities for the development of new classes of drugs. For these opportunities to be fully capitalized upon, investigators must choose molecular targets for drug development that are likely to yield attractive therapeutic profiles. This will require rapid and effective determination of gene functions in multiple cellular settings. The development of antisense oligonucleotides as specific inhibitors of gene expression should allow such determination of gene function. In addition, the antisense oligonucleotides themselves will likely prove useful as drugs. In this review, we discuss some of the issues surrounding the use of antisense oligonucleotides as research tools to help elucidate gene function, and highlight some of the approaches that can be taken to generate and use effective antisense reagents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454217     DOI: 10.1016/s0163-7258(99)00002-9

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  7 in total

1.  Stimulation of FSHbeta transcription by blockade of endogenous pituitary follistatin production: Efficacy of adenoviral-delivered antisense RNA in the rat.

Authors:  Daniel J Haisenleder; Kevin W Aylor; Laura L Burger; Alan C Dalkin; John C Marshall
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

2.  [Combination treatment with antisense oligonucleotides and chemotherapy in vitro].

Authors:  I Kausch; N Ewerdwalbesloh; H Jiang; C Doehn; S Krüger; D Jocham
Journal:  Urologe A       Date:  2005-08       Impact factor: 0.639

3.  Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation.

Authors:  Xian Zhang; Jian-Hua Zhang; Xu-Yang Chen; Qing-Hua Hu; Ming-Xing Wang; Rui Jin; Qing-Yu Zhang; Wei Wang; Rong Wang; Lin-Lin Kang; Jin-Sheng Li; Meng Li; Ying Pan; Jun-Jian Huang; Ling-Dong Kong
Journal:  Antioxid Redox Signal       Date:  2015-04-01       Impact factor: 8.401

4.  NR1 knockdown reveals CA1 injury during a developmental period of high seizure susceptibility despite reduced seizure activity.

Authors:  J Kaur; R Keesey; B Magrys; H Liu; L K Friedman
Journal:  Neuromolecular Med       Date:  2007-08-14       Impact factor: 3.843

5.  Utilizing antagomiR (antisense microRNA) to knock down microRNA in murine bone marrow cells.

Authors:  Chinavenmeni S Velu; H Leighton Grimes
Journal:  Methods Mol Biol       Date:  2012

Review 6.  RNA therapeutics for cardiovascular disease.

Authors:  Christian Boada; Roman Sukhovershin; Roderic Pettigrew; John P Cooke
Journal:  Curr Opin Cardiol       Date:  2021-05-01       Impact factor: 2.161

7.  Expression of RNA-interference/antisense transgenes by the cognate promoters of target genes is a better gene-silencing strategy to study gene functions in rice.

Authors:  Jing Li; Dagang Jiang; Hai Zhou; Feng Li; Jiawei Yang; Laifa Hong; Xiao Fu; Zhibin Li; Zhenlan Liu; Jianming Li; Chuxiong Zhuang
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.